Chirurgical Intervention, Thrombocytopaenia
Conditions
Keywords
Thrombocytopenia, Cardiac Surgery, Growth Factor, Patient Blood Management
Brief summary
Romiplostim has demonstrated its efficacy and good tolerance in multiple indications. If the efficacy of Romiplostim is confirmed in this population, thrombocytopenic patients will be able to undergo cardiac surgery, which is generally life-saving, without prior thrombocytopenia. Patients included in the study will be hospitalized within 15 days of the first administration of the study treatment and will be closely monitored clinically and biologically for at least 10 days after surgery. The occurrence of an adverse event can therefore be quickly detected and managed. Collectively, Patient Blood Management strategies are mainly focused on the management of preoperative anemia. If positive, this study will enrich the therapeutic arsenal available for optimizing patients in preparation for major surgery. As no major collective complications are expected, the collective benefit/risk ratio also appears favorable.
Interventions
Sponsors
Nantes University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients with no upper age limit, * Scheduled cardiac surgery with cardiopulmonary bypass, * Patients with preoperative thrombocytopenia strictly \<150,000/mm3 * Surgery performed with a blood recovery system using centrifugation (Cell Saver type) or equivalent, * Feasibility of a first injection (Romiplostim or Placebo) between D-14 and D-10 before surgery, * Surgery requiring the administration of antiplatelet and/or anticoagulant therapy for a minimum of 1 month postoperatively.
Exclusion criteria
* Inability to administer the first injection of Romiplostim or Placebo within 10 days prior to surgery, * Cardiac surgery without cardiopulmonary bypass, * Coronary artery bypass grafting due to one or more significant coronary stenoses, * Tangential filtration blood recovery system (i-SEP SAME® type) planned for intraoperative use or absence of intraoperative blood recovery system due to investigator choice or availability issues, * Planned use of aprotinin as an antifibrinolytic agent during surgery, * Patient with contraindication to discontinuation of all antiplatelet therapy before surgery (with discontinuation at least 3 days before surgery for acetylsalicylic acid and at least 5 days before surgery for clopidogrel/ticagrelor), * Hereditary or acquired thrombophilia with or without a history of thrombosis, * History of ischemic or hemorrhagic stroke, * History of phlebitis, pulmonary embolism, or portal vein thrombosis, * History of heart attack with stent placement less than one year ago, * Current limb immobilization (e.g., plaster cast for ankle fracture) or inability to walk independently due to limited mobility (e.g., paralysis), * Current immobilization of a limb (e.g., plaster cast for ankle fracture) or inability to walk independently due to motor limitation (e.g., complete paralysis of a limb) or medical contraindication (e.g., strict bed rest required), * Myelogram indicating malignant hematological disease or blast cells strictly greater than 5%, * Malignant diseases with last follow-up indicating disease progression, * Severe chronic liver disease with a CHILD-PUGH score \> 6 (measured without decompensation), * Treatment with thrombopoietin receptor agonist received within 3 months prior to inclusion, * Treatment with JAK2 inhibitor currently underway or within the last month, * Treatment with Rituximab within the last 7.5 months or intravenous immunoglobulin within the last 40 days, * Ongoing treatment with corticosteroids at doses equal to or greater than 20mg of hydrocortisone, 5mg of prednisone/or prednisolone, 4mg of methylprednisone, or 0.75mg of dexamethasone, * Known hemophilia, * Hypersensitivity to romiplostim or any of its excipients, or to proteins derived from E. coli, * Context of hyperchloremia, hypernatremia, or major water and salt retention with anasarca refractory to medical treatment, * Pregnant women or women of childbearing age who are not using effective contraception, * Currently using combined oral contraceptive pills or oral hormone replacement therapy containing estrogen, * Breastfeeding women, * Minors, * Adults under guardianship, curatorship, or judicial protection, * Patients who do not speak French, * Patients without Social Security coverage.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy | Day 7 | Lowest platelet count measured between the end of ECC and the 7th postoperative day with D0 = day of surgery |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy | Day 28 | Lowest platelet count measured between the end of ECC and the 28th postoperative day with D0 = day of surgery |
| Transfusion of platelet concentrate | Day 1 | Number of transfusion of platelet concentrate |
| Transfusion of red blood cell concentrate | Day 1 | Number of transfusion of red blood cell concentrate |
| Transfusion of fresh frozen plasma | Day 1 | Number of transfusion of fresh frozen plasma |
| Administration of blood-derived drugs | Day 1 | Number of administration of blood-derived drugs |
| Bleeding volume | Hour 12 | Post-operative bleeding volume from sternal closure to 12th post-operative hour |
| Mortality | Day 28 | Rate of mortality |
| Infection | Month 3 | Rate of infection |
| Lowest haemoglobin | Day 7 | Lowest haemoglobincount measured between the end of ECC and the 7th postoperative day with D0 = day of surgery |
Countries
France
Contacts
Primary ContactJean- Christophe RIGAL
Backup ContactAstrid GARREAU
Outcome results
None listed